Comparison of the efficacy and comfort of high-flow nasal cannula with different initial flow settings in patients with acute hypoxemic respiratory failure: a systematic review and network meta-analysis

被引:2
|
作者
He, Yuewen [1 ,2 ]
Zhuang, Xuhui [1 ,2 ]
Liu, Hao [1 ,2 ]
Ma, Wuhua [2 ]
机构
[1] Guangzhou Univ Chinese Med, Guangzhou, Guangdong, Peoples R China
[2] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Dept Anesthesiol, 12 Jichang Rd, Guangzhou 510405, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
High-flow nasal cannula; Acute hypoxemic respiratory failure; Network meta-analysis; OXYGEN-THERAPY; IMMUNOCOMPROMISED PATIENTS; MECHANICAL VENTILATION; DISTRESS-SYNDROME; PRESSURE; COVID-19; SUPPORT;
D O I
10.1186/s40560-023-00667-2
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
BackgroundHigh-flow nasal cannula (HFNC) has been proven effective in improving patients with acute hypoxemic respiratory failure (AHRF), but a discussion of its use for initial flow settings still need to be provided. We aimed to compare the effectiveness and comfort evaluation of HFNC with different initial flow settings in patients with AHRF.MethodsStudies published by October 10, 2022, were searched exhaustively in PubMed, Embase, Web of Science, Cochrane Library (CENTRAL), and the China National Knowledge Infrastructure (CNKI) database. Network meta-analysis (NMA) was performed with STATA 17.0 and R software (version 4.2.1). A Bayesian framework was applied for this NMA. Comparisons of competing models based on the deviance information criterion (DIC) were used to select the best model for NMA. The primary outcome is the intubation at day 28. Secondary outcomes included short-term and long-term mortality, comfort score, length of ICU or hospital stay, and 24-h PaO2/FiO(2).ResultsThis NMA included 23 randomized controlled trials (RCTs) with 5774 patients. With NIV as the control, the HFNC_high group was significantly associated with lower intubation rates (odds ratio [OR] 0.72 95% credible interval [CrI] 0.56 to 0.93; moderate quality evidence) and short-term mortality (OR 0.81 95% CrI 0.69 to 0.96; moderate quality evidence). Using HFNC_Moderate (Mod) group (mean difference [MD] - 1.98 95% CrI -3.98 to 0.01; very low quality evidence) as a comparator, the HFNC_Low group had a slight advantage in comfort scores but no statistically significant difference. Of all possible interventions, the HFNC_High group had the highest probability of being the best in reducing intubation rates (73.04%), short-term (82.74%) and long-term mortality (67.08%). While surface under the cumulative ranking curve value (SUCRA) indicated that the HFNC_Low group had the highest probability of being the best in terms of comfort scores.ConclusionsThe high initial flow settings (50-60 L/min) performed better in decreasing the occurrence of intubation and mortality, albeit with poor comfort scores. Treatment of HFNC for AHRF patients ought to be initiated from moderate flow rates (30-40 L/min), and individualized flow settings can make HFNC more sensible in clinical practice.
引用
收藏
页数:23
相关论文
共 50 条
  • [21] The efficacy and safety of high-flow nasal cannula therapy in patients with COPD and type II respiratory failure: a meta-analysis and systematic review
    Xu, Zhiping
    Zhu, Lingxia
    Zhan, Jingye
    Liu, Lijun
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2021, 26 (01)
  • [22] The efficacy and safety of high-flow nasal cannula therapy in patients with COPD and type II respiratory failure: a meta-analysis and systematic review
    Zhiping Xu
    Lingxia Zhu
    Jingye Zhan
    Lijun Liu
    European Journal of Medical Research, 26
  • [23] High-Flow Nasal Cannula Therapy for Acute Hypoxemic Respiratory Failure in Adults: A Retrospective Analysis
    Cho, Woo Hyun
    Yeo, Hye Ju
    Yoon, Seong Hoon
    Lee, SeungEun
    SooJeon, Doo
    Kim, Yun Seong
    Kim, Ki Uk
    Lee, Kwangha
    Park, Hye Kyung
    Lee, Min Ki
    INTERNAL MEDICINE, 2015, 54 (18) : 2307 - 2313
  • [24] Predictors of success of high-flow nasal cannula in the treatment of acute hypoxemic respiratory failure
    Artacho Ruiz, R.
    Artacho Jurado, B.
    Caballero Gueto, F.
    Cano Yuste, A.
    Durban Garcia, I
    Garcia Delgado, F.
    Guzman Perez, J. A.
    Lopez Obispo, M.
    Quero del Rio, I
    Rivera Espinar, F.
    del Campo Molina, E.
    MEDICINA INTENSIVA, 2021, 45 (02) : 80 - 87
  • [25] A Skeptical Perspective on High-Flow Nasal Cannula in the Treatment of Acute Hypoxemic Respiratory Failure
    Roberts, Christopher D.
    Oeckler, Richard A.
    RESPIRATORY CARE, 2015, 60 (10) : 1522 - 1525
  • [26] High Flow Nasal Cannula Oxygen Therapy for Acute Hypoxemic Respiratory Failure: A Systematic Review
    Algamdi, Mohmmed
    Ball, Ian
    CHEST, 2016, 150 (04) : 306A - 306A
  • [27] Physiological Comparison of High-Flow Nasal Cannula and Helmet Noninvasive Ventilation in Acute Hypoxemic Respiratory Failure
    Grieco, Domenico Luca
    Menga, Luca S.
    Raggi, Valeria
    Bongiovanni, Filippo
    Anzellotti, Gian Marco
    Tanzarella, Eloisa S.
    Bocci, Maria Grazia
    Mercurio, Giovanna
    Dell'Anna, Antonio M.
    Eleuteri, Davide
    Bello, Giuseppe
    Maviglia, Riccardo
    Conti, Giorgio
    Maggiore, Salvatore Maurizio
    Antonelli, Massimo
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201 (03) : 303 - 312
  • [28] High-Flow Nasal Cannula in Critically Ill Subjects With or at Risk for Respiratory Failure: A Systematic Review and Meta-Analysis
    Nedel, Wagner Luis
    Deutschendorf, Caroline
    Rodrigues Filho, Edison Moraes
    RESPIRATORY CARE, 2017, 62 (01) : 123 - 132
  • [29] Can High-Flow Nasal Cannula Improve Comfort in Elderly Patients with Acute Respiratory Failure?
    Makino, H.
    Nishikawa, H.
    Taguchi, Y.
    Kouda, T.
    Kajiwara, K.
    Kanematsu, T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [30] High-flow nasal cannula reduces intubation rate in patients with COVID-19 with acute respiratory failure: a meta-analysis and systematic review
    Li, Yang
    Li, Cong
    Chang, Wei
    Liu, Ling
    BMJ OPEN, 2023, 13 (03):